Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Phase 3, Randomized, Multi-center, Double-blind, Double-dummy Study of Efficacy, Tolerability & Safety of Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Treatment of cUTI in Adults

Next Previous
X
Search
Trial Profile

Prospective, Phase 3, Randomized, Multi-center, Double-blind, Double-dummy Study of Efficacy, Tolerability & Safety of Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Treatment of cUTI in Adults

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sulopenem (Primary) ; Sulopenem (Primary) ; Sulopenem (Primary) ; Sulopenem (Primary) ; Amoxicillin/clavulanic acid; Ciprofloxacin; Ertapenem
  • Indications Pyelonephritis; Urinary tract infections
  • Focus Registrational; Therapeutic Use
  • Acronyms SURE 2
  • Sponsors Iterum Therapeutics

    • Most Recent Events

    • 19 Jun 2023 Results (n=884) characterizing the beta lactamase content of select; Enterobacterales isolates recovered from patients enrolled in this trial presented at the ASM Microbe 2023
    • 07 Sep 2022 Results assessing efficacy of sulopenem followed by sulopenem-etzadroxil/probenecid versus ertapenem followed by ciprofloxacin for the treatment of complicated urinary tract infections (cUTI) in adults, published in the Clinical Infectious Diseases.
    • 12 Nov 2021 According to an Iterum Therapeutics media release, the company has requested a Type B meeting with the FDA to discuss the design of a potential new clinical trial to support such potential resubmission.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top